Anna M. Sawka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna M. Sawka has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- David Paul Goldstein
Temerty Faculty of Medicine University of Toronto Toronto Ontario Canada
4 shared publications - Amiram Gafni
McMaster University
3 shared publications Jie Su
Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
3 shared publications- Nancy Noel Baxter
University of Sydney 2 Faculty of Medicine and Health Camperdown, Australia
3 shared publications Afshan Zahedi
Division of Endocrinology, Women’s College Hospital and University of Toronto, Toronto, Ontario, Canada
2 shared publicationsAlyse S. Goldberg
Sunnybrook Health Sciences Centre
2 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 160 (10) , 1117
Long-Term Durability of Active Surveillance of Small, Low-Risk Papillary Thyroid Cancer
Importance: In managing early-stage cancers, active surveillance (AS) may be preferentially favored by older individuals. In counseling patients, it is important to understand the durability of AS in the context of age.Objective: To evaluate the durability of AS in patients with small, low-risk papillary thyroid cancer (PTC) according to age at the time of choosing AS.Design, Setting, and Participants: This single-center, prospective, long-term follow-up cohort study was conducted at a tertiary care hospital in Toronto, Ontario, Canada. Adult patients with small, localized, low-risk PTC less than 2 cm in maximal diameter were enrolled between May 2016 and February 2021. The clinical outcome data were analyzed up to the time point of May 25, 2025, and final data analysis was performed in June 2025.Exposure: All patients were offered the choice of AS or thyroid surgery.Main Outcomes and Measures: The primary outcome was the overall rate of AS crossover to definitive treatment (treatment completed or recommended by an investigator) and the indications. Cumulative crossover incidence function curves were examined according to age, with death from other causes as the competing risk.Results: A total of 200 patients (155 patients under AS and 45 who had immediate surgery) were followed up for a median (IQR) duration of 71 (59-84) months. Overall mean (SD) age was 52.0 (14.9) years, and 153 patients (76.5%) were female. There were no observed thyroid cancer–related deaths or any distant metastatic disease. The overall crossover rate from AS was 23.9% (37/155; 32 completed treatment, 3 declined surgery for disease progression, and 2 awaiting treatment). Crossover reasons included disease progression (56.8% [21/37]), patient preference (40.5% [15/37]), and ultrasound imaging limitations precluding accurate tumor measurement under active surveillance (tumor border not clearly distinguishable from heterogeneous echotexture of the thyroid parenchyma in a patient with Hashimoto thyroiditis; 2.6% [1/37]). The 5-year age-stratified cumulative overall crossover incidence rates were 41.5% (95% CI, 25.6%-56.8%) in patients younger than 45 years, 20.9% (95% CI, 12.3%-31.1%) in those aged 45 to 64 years, and 5.1% (95% CI, 0.9%-15.2%) in those aged 65 years and older (P < .001).Conclusion and Relevance: This single-center Canadian cohort study found that AS is a durable long-term management strategy for small, low -risk PTC, particularly in older individuals. Older individuals may be less likely to cross over to surgery after choosing AS.
- 1 October 2025
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 160 (10) , 1117
Open AccessLong-Term Durability of Active Surveillance of Small, Low-Risk Papillary Thyroid Cancer
Importance: In managing early-stage cancers, active surveillance (AS) may be preferentially favored by older individuals. In counseling patients, it is important to understand the durability of AS in the context of age.Objective: To evaluate the durability of AS in patients with small, low-risk papillary thyroid cancer (PTC) according to age at the time of choosing AS.Design, Setting, and Participants: This single-center, prospective, long-term follow-up cohort study was conducted at a tertiary care hospital in Toronto, Ontario, Canada. Adult patients with small, localized, low-risk PTC less than 2 cm in maximal diameter were enrolled between May 2016 and February 2021. The clinical outcome data were analyzed up to the time point of May 25, 2025, and final data analysis was performed in June 2025.Exposure: All patients were offered the choice of AS or thyroid surgery.Main Outcomes and Measures: The primary outcome was the overall rate of AS crossover to definitive treatment (treatment completed or recommended by an investigator) and the indications. Cumulative crossover incidence function curves were examined according to age, with death from other causes as the competing risk.Results: A total of 200 patients (155 patients under AS and 45 who had immediate surgery) were followed up for a median (IQR) duration of 71 (59-84) months. Overall mean (SD) age was 52.0 (14.9) years, and 153 patients (76.5%) were female. There were no observed thyroid cancer–related deaths or any distant metastatic disease. The overall crossover rate from AS was 23.9% (37/155; 32 completed treatment, 3 declined surgery for disease progression, and 2 awaiting treatment). Crossover reasons included disease progression (56.8% [21/37]), patient preference (40.5% [15/37]), and ultrasound imaging limitations precluding accurate tumor measurement under active surveillance (tumor border not clearly distinguishable from heterogeneous echotexture of the thyroid parenchyma in a patient with Hashimoto thyroiditis; 2.6% [1/37]). The 5-year age-stratified cumulative overall crossover incidence rates were 41.5% (95% CI, 25.6%-56.8%) in patients younger than 45 years, 20.9% (95% CI, 12.3%-31.1%) in those aged 45 to 64 years, and 5.1% (95% CI, 0.9%-15.2%) in those aged 65 years and older (P < .001).Conclusion and Relevance: This single-center Canadian cohort study found that AS is a durable long-term management strategy for small, low -risk PTC, particularly in older individuals. Older individuals may be less likely to cross over to surgery after choosing AS.
- Open Access
- 24 May 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (5) , 626-634
Decision Regret Following the Choice of Surgery or Active Surveillance for Small, Low-Risk Papillary Thyroid Cancer: A Prospective Cohort Study
Background: It is important to understand cancer survivors' perceptions about their treatment decisions and quality of life. Methods: We performed a prospective observational cohort study of Canadian patients with small (p = 0.730) or adjusted ( p = 0.29) analyses. However, the adjusted level of decision regret was significantly higher in patients who initially chose AS and crossed over to surgery (beta coefficient 10.1 [confidence interval; CI 1.3–18.9], p = 0.02), compared with those remaining under AS. In secondary adjusted analyses, respondents who chose surgery reported that symptoms related to their cancer or its treatment interfered with life to a greater extent than those who chose AS ( p = 0.02), but there were no significant group differences in the levels of depression, anxiety, fear of disease progression, or overall body image perception. Conclusions: In this study of patients with small, low-risk PTC, the mean level of decision regret pertaining to the initial disease management choice was relatively low after one year and it did not differ significantly for respondents who chose AS or surgery.
- 24 May 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (5) , 626-634
Open AccessDecision Regret Following the Choice of Surgery or Active Surveillance for Small, Low-Risk Papillary Thyroid Cancer: A Prospective Cohort Study
Background: It is important to understand cancer survivors' perceptions about their treatment decisions and quality of life. Methods: We performed a prospective observational cohort study of Canadian patients with small (p = 0.730) or adjusted ( p = 0.29) analyses. However, the adjusted level of decision regret was significantly higher in patients who initially chose AS and crossed over to surgery (beta coefficient 10.1 [confidence interval; CI 1.3–18.9], p = 0.02), compared with those remaining under AS. In secondary adjusted analyses, respondents who chose surgery reported that symptoms related to their cancer or its treatment interfered with life to a greater extent than those who chose AS ( p = 0.02), but there were no significant group differences in the levels of depression, anxiety, fear of disease progression, or overall body image perception. Conclusions: In this study of patients with small, low-risk PTC, the mean level of decision regret pertaining to the initial disease management choice was relatively low after one year and it did not differ significantly for respondents who chose AS or surgery.
- Open Access
- 6 July 2023
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 149 (9) , 803-810
Gender Differences in Fears Related to Low-Risk Papillary Thyroid Cancer and Its Treatment
Individuals diagnosed with thyroid cancer are known to experience distressing emotions, including shock, fear, and anxiety.1-3 Concerns expressed by patients with newly diagnosed low-risk papillary thyroid cancer (PTC) relate to the cancer and its associated future outcome uncertainty as well as the potential risks and consequences of its treatment (eg, thyroidectomy).4 It is important to fully understand the fears experienced by individuals newly diagnosed with thyroid cancer to inform supportive care strategies and patient counseling. This understanding may be more fully informed in considering the context of gender.
- 6 July 2023
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 149 (9) , 803-810
Open AccessGender Differences in Fears Related to Low-Risk Papillary Thyroid Cancer and Its Treatment
Individuals diagnosed with thyroid cancer are known to experience distressing emotions, including shock, fear, and anxiety.1-3 Concerns expressed by patients with newly diagnosed low-risk papillary thyroid cancer (PTC) relate to the cancer and its associated future outcome uncertainty as well as the potential risks and consequences of its treatment (eg, thyroidectomy).4 It is important to fully understand the fears experienced by individuals newly diagnosed with thyroid cancer to inform supportive care strategies and patient counseling. This understanding may be more fully informed in considering the context of gender.
- 1 January 2023
- Published by SAGE Publications in Thyroid®
- Vol. 33 (1) , 9-10
The Beginning of the American Thyroid Association Centennial Year
- 1 January 2023
- Published by SAGE Publications in Thyroid®
- Vol. 33 (1) , 9-10
The Beginning of the American Thyroid Association Centennial Year
- 18 July 2022
- Published by Wolters Kluwer Health in Current Opinion in Endocrinology, Diabetes and Obesity
- Vol. 29 (5) , 492-496
Women and thyroid cancer incidence: overdiagnosis versus biological risk
Purpose of the review: Our aim is to discuss the concepts of sex and gender in the context of thyroid cancer epidemiology. Recent findings: It has been long-established in global epidemiologic data that thyroid cancer incidence rates are higher in women than men. However, what has been less well understood is whether this reflects sex disparities in cancer susceptibility, gender disparities in detection, or a combination. A recent meta-analysis of autopsy data from individuals who were not known to have thyroid cancer in their lifetime demonstrated no difference in the prevalence of thyroid cancer in women and men, suggesting that gender differences may be the reason for gender-based differences in thyroid cancer detection. This finding, and sex differences in auto immunity and other factors that may affect cancer susceptibility are explored. Summary: Additional research to explore gender- and sex-specific data on thyroid cancer would inform our understanding of the differences and similarities between men and women in susceptibility and detection of thyroid cancer and help to optimize disease management for all genders and both sexes.
- 18 July 2022
- Published by Wolters Kluwer Health in Current Opinion in Endocrinology, Diabetes and Obesity
- Vol. 29 (5) , 492-496
Women and thyroid cancer incidence: overdiagnosis versus biological risk
Purpose of the review: Our aim is to discuss the concepts of sex and gender in the context of thyroid cancer epidemiology. Recent findings: It has been long-established in global epidemiologic data that thyroid cancer incidence rates are higher in women than men. However, what has been less well understood is whether this reflects sex disparities in cancer susceptibility, gender disparities in detection, or a combination. A recent meta-analysis of autopsy data from individuals who were not known to have thyroid cancer in their lifetime demonstrated no difference in the prevalence of thyroid cancer in women and men, suggesting that gender differences may be the reason for gender-based differences in thyroid cancer detection. This finding, and sex differences in auto immunity and other factors that may affect cancer susceptibility are explored. Summary: Additional research to explore gender- and sex-specific data on thyroid cancer would inform our understanding of the differences and similarities between men and women in susceptibility and detection of thyroid cancer and help to optimize disease management for all genders and both sexes.
- 17 March 2022
- Published by SAGE Publications in Thyroid®
- Vol. 32 (3) , 223
A Note of Thanks on International Women's Day
- 17 March 2022
- Published by SAGE Publications in Thyroid®
- Vol. 32 (3) , 223
A Note of Thanks on International Women's Day
- 21 December 2021
- Published by SAGE Publications in Thyroid®
- Vol. 32 (1) , 1-2
Transfer of Stewardship of Thyroid
- 21 December 2021
- Published by SAGE Publications in Thyroid®
- Vol. 32 (1) , 1-2
Transfer of Stewardship of Thyroid
- Open Access
Decision-making in Surgery or Active Surveillance for Low Risk Papillary Thyroid Cancer During the COVID-19 Pandemic
We describe our experience conducting a prospective observational cohort study on the management of small, low risk papillary thyroid cancer during the COVID-19 pandemic. Our study participants are given the choice of active surveillance (AS) or surgery, and those in the AS arm are followed at the study center, whereas surgical patients undergo usual care. During the pandemic we have transitioned from in-person research patient visits to largely virtual care of patients under AS. As of 30 October 2020, we had enrolled 181 patients enrolled in our study (including 25 during the pandemic), of which 92.3% (167/181) consented to telephone communication and 79.0% (143/181) consented to secure videoconferencing communication. Prior to the pandemic, 74.5% (117/157) of our patients chose AS over surgery, whereas during the pandemic, 96.0% (24/25) chose AS. Of the 133 study patients who were under AS within the timeframe from 12 March 2020, to 30 October 2020, the percentage of patients who missed appointments was 8.3% (11/133, for neck ultrasound and physician visits, respectively) and delayed appointments was 23.3% (31/133). This preliminary data suggests that prospective observational research on AS of thyroid cancer can safely continue during the pandemic.
Open AccessDecision-making in Surgery or Active Surveillance for Low Risk Papillary Thyroid Cancer During the COVID-19 Pandemic
We describe our experience conducting a prospective observational cohort study on the management of small, low risk papillary thyroid cancer during the COVID-19 pandemic. Our study participants are given the choice of active surveillance (AS) or surgery, and those in the AS arm are followed at the study center, whereas surgical patients undergo usual care. During the pandemic we have transitioned from in-person research patient visits to largely virtual care of patients under AS. As of 30 October 2020, we had enrolled 181 patients enrolled in our study (including 25 during the pandemic), of which 92.3% (167/181) consented to telephone communication and 79.0% (143/181) consented to secure videoconferencing communication. Prior to the pandemic, 74.5% (117/157) of our patients chose AS over surgery, whereas during the pandemic, 96.0% (24/25) chose AS. Of the 133 study patients who were under AS within the timeframe from 12 March 2020, to 30 October 2020, the percentage of patients who missed appointments was 8.3% (11/133, for neck ultrasound and physician visits, respectively) and delayed appointments was 23.3% (31/133). This preliminary data suggests that prospective observational research on AS of thyroid cancer can safely continue during the pandemic.
- 16 December 2020
- Published by Springer Nature
- p. 69-80
Papillary Thyroid Cancer with Central Neck Lymph Node Metastases
- 16 December 2020
- Published by Springer Nature
- p. 69-80
Papillary Thyroid Cancer with Central Neck Lymph Node Metastases
- 16 October 2020
- Published by SAGE Publications in Thyroid®
- Vol. 30 (10) , 1542-1543
Response to Miyauchi et al. re: “A Prospective Mixed-Methods Study of Decision Making on Surgery or Active Surveillance for Low-Risk Papillary Thyroid Cancer”
- 16 October 2020
- Published by SAGE Publications in Thyroid®
- Vol. 30 (10) , 1542-1543
Response to Miyauchi et al. re: “A Prospective Mixed-Methods Study of Decision Making on Surgery or Active Surveillance for Low-Risk Papillary Thyroid Cancer”